Cue Biopharma Brings Autoimmune Back To The Fore With Ono Deal

 
• By Alaric DeArment

Deal Snapshot: Cue’s pipeline is heavy on oncology, but it partnered with Merck on autoimmune in 2017 and while that work has shifted to cancer, the Ono partnership puts the focus back on autoimmune disease.

Cue and Ono announced a deal to develop Cue's bispecific fusion protein for autoimmune disease • Source: Shutterstock

More from Deals

More from Business